UBS reaffirms Buy for Kura Oncology stock at USD 15 target

UBS reiterated a Buy rating and a USD 15.00 price target for Kura Oncology on October 5, 2026, according to Investing.com. The call puts renewed attention on the launch of KOMZIFTI and the company's transition into a commercial-stage oncology business.

Revenue beats second-quarter estimates

Kura reported USD 20.87 million of revenue in the second quarter of 2026, above the USD 20.16 million consensus cited by Investing.com. The company also posted an adjusted loss of USD 0.77 per share, compared with an expected loss of USD 0.88.

The revenue result gives the commercial story a measurable base, while the loss shows that launch economics remain a central part of the investment case. Kura's cash and cash equivalents stood at USD 70.2 million on June 30, 2026, and operating cash flow was negative USD 62.5 million in the second quarter.

Analysts set wider valuation markers

JPMorgan initiated coverage at Overweight with a USD 30.00 year-end price target on October 1, 2026, as CNBC reported. That target was 180.11 percent above the USD 10.71 reference price cited in the report.

CNBC also reported that net product revenue rose from USD 2.10 million in the final five weeks of 2025 to USD 9.10 million in the second quarter of 2026. The comparison matters because the launch trajectory, rather than a mature profit margin, is currently the clearest operating signal.

Kura's primary Nasdaq listing last stood at USD 10.53 on October 6, 2026 at 4:00 p.m. ET. The finance snapshot places its market capitalization at USD 934.8 million, with a 52-week range of USD 7.36 to USD 13.90.

Stock reference remains dated

The last Lang & Schwarz close was EUR 9.39 on October 5, 2026. The quote data dated October 6, 2026 did not provide a valid current-session price or daily percentage for October 7, 2026.

The further course of trading is shown by the continuously updated real-time quote of Kura Oncology stock.

More news and analyses on Kura Oncology stock